Try our Advanced Search for more refined results
Life Sciences - December, 2017
240 articles
- Ex-Katten Attorney Convicted Of Aiding Shkreli Fraud
- Ex-Katten Atty's Trial Heads To Jury For The Holidays
- Self-Made IP No Longer Deemed Capital Asset In New Tax Law
- Eli Lilly Escapes Testosterone MDL With Settlement Deal
- Judge Throws Out $150M AbbVie AndroGel Verdict
- Roche Inks $1.7B Deal For Calif. Cancer-Drug Maker
- La. Not Bound By Flonase Antitrust Settlement: 3rd Circ.
- Trump Signs $1.5T Tax Cut Legislation
- 5 Most-Read Legal Industry Articles Of 2017
- Novartis Could Be On Hook For Generic Drug: Calif. Justices
- NC Sues Insys Over Scheme To Push Powerful Opioid
- Ex-Katten Atty Cites 'Walls' Of Doubt As Trial Nears End
- Landlord Issues Punted In Vitamin World's $28M Sale Order
- Shire FCA Deal Doesn't Cover 'Unique' Claims, Relator Says
- Raytheon Says Settlement Ended Bedford Clean-Up Liability
- Hospitals Urge Judge to Halt $1.6B Cut to Drug Payments
- Calif. Bank & Trust Beats Suit Over Depositor's Ponzi Scheme
- Aerkomm Hopes $40M Public Offering Will Fly With Investors
- Arbitrators Can't Demand Third-Party Docs, 9th Circ. Says
- Spoliation Scrutiny: Disparate Standards For Distinct Mediums
- Full Fed Circ. Won't Review Boston Sci Win In $200M IP Suit
- Cancer-Focused Biopharma Co. Tallies $60M Funding Round
- Where 5 Top MDLs Stand At The End Of 2017
- Valeant Gets To Arbitrate Ex-CEO's 3M Unpaid Shares Claim
- Allergan Seeks To Pause Antitrust Suits Pending MDL Call
- The Latest FDA Move To Limit Digital Health Software Regs
- Feds To Retry Ex-Biotech Exec After Mistrial In Fraud Case
- Drugmakers Ducked $1.3B In Medicaid Rebates, OIG Says
- Tribunal Lacked Power To Nix $135M Claim, Softgel Co. Says
- Greebel 'Greased Wheels' For Shkreli, Feds Say At Closing
- Nutraceutical Investors Demand Appraisal After $446M Buy
- J&J Fined €25M Over French Generic Drug Smear Campaign
- Sens. Target Small Drugmaker Over 300-Fold Price Hike
- United Therapeutics Settles Charity-Kickback Claim For $210M
- Judge OKs $700K Settlement Over Montel-Endorsed Clothes
- Baxter Healthcare's Waste Overpolluted Water, Ill. AG Says
- Boehringer To Pay $13.5M To End Off-Label Marketing Claims
- TM Dilution Claims Over Trojan Condoms' 'XOXO' Tossed
- Medical Co. Slams Whistleblower's 'Backward' Appeal Bid
- Bayer, Merck Accused Of Falsely Advertising Sunblock's SPF
- Exploring Viability Of 'Diagnose And Treat' Method Claims
- 'Patent Dance' Ruling Means Sponsors Must Plan Ahead
- House Sends $1.5T Tax Cut Bill To Trump's Desk
- FCPA Enforcement Picks Up In 2nd Half Of 2017
- Hearing The Need For More Women's Voices In The Courtroom
- Telehealth In 2017: What Changed And What's Ahead
- GOP Tax Cut Bill Nears Finish Line After Senate Passage
- With Another Flap, Greebel Fraud Trial Heads To Closings
- FCA Suit Against Sleep-Testing Co. Rouses The Feds
- Sandoz Gets Early Win In Amgen IP Dispute Over Neulasta
- Meningitis Outbreak MDL, $200M Settlement Fund Near End
- FDA Warning Wire: Zika, Tattoos, Syringes, Supplements
- Zurich Doesn't Owe On Sexual Harassment Payouts: Judge
- Deals Rumor Mill: CJ HealthCare, Vitamin World, Time Warner
- Dr. Reddy's To Pay $5M To End Feds' Packaging Safety Suit
- MVP: Fish & Richardson's Dorothy Whelan
- House Must Vote Again On Final GOP Tax Bill
- Grant & Eisenhofer Fee Fight Halts $73M Celgene FCA Payout
- Tribe, Generics Spar Over PTAB Amici In Allergan Patent Row
- Ex-Biotech Exec Denies Tie To Mass. Securities Scheme
- FDA Vows Crackdown On Homeopathic Treatments
- Sandoz Says Neulasta Biosimilar Doesn't Infringe Amgen IP
- 2nd Circ. Affirms Dismissal Of FCA Suit Against Amgen
- PTAB To Rehear Cook Challenge To Internal-Bleed Device IP
- Bayer Slams 'Killinnazis' Posts In $28M Xarelto Injury Case
- Fed. Circ. Upholds Genzyme's Win In Stem Cell Patent Case
- $10M Pepcid Patent Verdict Nixed As Judge Reverses Herself
- MVP: Gibson Dunn's Jane Love
- Prevagen Maker Must Face Certified Class In Labeling Suit
- 40 Years Of FCPA
- How 2 Devices And 1 Domain Changed My Practice In 2017
- Fed. Circ. Says PTAB Erred In Axing Hospital Bed Patent
- Top Product Liability Cases Of 2017
- Bayer, Belmora Spar Over TM, Antitrust Bids In Flanax Feud
- Russian Award's OK Is Nigh For No-Show Pharma Biz
- Pa. Man Cops To Celator Insider Trading Scheme
- Mitsubishi Says Generics Co.'s ANDA Infringes Diabetes Med
- Artificial Knee Co. Can't Trim $16M Injury Damages Further
- Could A High Court Case Blunt AIA Tribal Immunity Defense?
- 17 Pharma And Food Tweets That Left A Mark In 2017
- PTAB Invalidates Hologic Patent, Rejects Claim Fixes
- Subsidiaries May Sway Patent Case Jurisdiction In Del.
- Final GOP Tax Bill Settles On 21% Corporate Rate
- Health Hires: Holland & Knight, EBG, Quarles, Ciitizen
- A Chat With Orrick COO Laura Saklad
- Alternative Fees: My Experience At Bartlit Beck
- Litigation Is Not The Solution To The Opioid Epidemic
- MVP: Goodwin's Stuart Cable
- US Calls Off The Dogs Following Thailand's IP Tweaks
- The Biggest Pennsylvania Court Decisions In 2017
- Does Indication-Specific Pricing Fit Generics With Carveouts?
- Jurors Should Have An Active Role In Trials
- Gov't Misconduct Claims Blocked From Ex-Katten Atty Trial
- NY High Court Says 'Wrongful Birth' Claims Start At Birth
- Mass. City Latest To Sue Pharma Cos. Over Opioid Crisis
- 3 Takeaways As Fed. Circ. Limits Biosimilar Lawsuits
- ITC To Probe Intraoral Scanners Over Patent Infringement
- Xarelto Bellwether Loser's New Trial Bid Rejected By Judge
- Boston Scientific Settles Nearly 350 Pelvic Mesh Suits
- Usage Of Uterine Device Down Since Warning, FDA Says
- MVP: Sullivan & Cromwell's Matthew Hurd
- Insurer Doesn't Owe For $2.8M Suit Against Medical Co.
- NC Prosthetics Co. Ran $12M Medicaid Fraud, Gov't Says
- J&J Unit Hit With $15M Pelvic Mesh Verdict In NJ
- Meningitis Fraudster Says Feds' Push For $133M Must Wait
- 40 Years Of FCPA: An Update From The DOJ
- Why Information Governance Is More Important Than Ever
- A Review Of Massachusetts' Marijuana Industry In 2017
- Biosimilar Act Trumps State Laws, Fed. Circ. Rules
- Cosmetic Companies Must Plan For New Regulation
- Partial Win Likely For Celgene In Mylan Antitrust Suit
- BigLaw Is Behind The Automation Curve
- Jury Urged To Punish J&J With Pelvic Mesh Trial Verdict
- 2nd Circ. Axes Pharma Exec's Fraud Convictions
- Cancer Immunotherapy Co. Nabs $62M To Advance Research
- Apotex Challenges Amgen Cancer Biologic Patent As Obvious
- Purdue Loses Bid To Fuse Jumble Of OxyContin Patent Suits
- Pa. Justices Won't Revive Zoloft Birth Injury Suit
- GSK Beats Heart Attack Suit In Diabetes Drug MDL
- Lessons On Losses From 3 Recent FCA Settlements
- Medtronic To Pay $12M To End Deceptive Advertising Suit
- How District Courts Split Over 'Infringing Acts'
- Biopharma Co. Allakos Nabs $100M In Funding Round
- 40 Years Of FCPA: Compliance, Past And Future
- Jury Sides With SEC, Finds Syringe Maker Juiced Stock
- State AGs Fight To Block Trump's Birth Control Rules
- Biopharm Ex-CEO Used Travel Funds For Hooters, SEC Says
- Ill. Doctor Gets 14 Mos. For Illegal Drug Distribution
- Calif. Surrogacy Agency Not Covered For Negligence Suit
- GOP Introduces 5 Bills To Delay Affordable Care Act Taxes
- Amgen Whistleblower Was Original Source, 2nd Circ. Told
- Retailers Settle Claims Against Teikoku In Lidoderm MDL
- Split Del. Justices OK Denial Of $50M Drug Approval Bonus
- Pharma Cos. Settle Pa. Skelaxin Pay-For-Delay Fight
- Fed. Circ. Affirms PTAB Ax Of Daiichi's Heart Drug Patents
- FDA Warning Wire: Chocolate 'Snuff' Sold As Street Drug Sub
- Actavis Asks Calif. Justices To Revive Opioid Coverage Bid
- 40 Years Of FCPA: Cross-Border Efforts And Growing Risk
- Judging A Book: Cooke Reviews 'Constance Baker Motley'
- Keeping Your Law Library Relevant In The Age Of Google
- Fed. Circ. Says It Can't Review PTAB Re-Exam Terminations
- Surgeon Tells Jury Complications Not Limited To J&J Mesh
- 6 Things You Need To Know About Millennial Jurors
- Has Litigation Finance Shed Its Stigma?
- Why Investors Are Taking The Leap To 3rd-Party Funding
- What Your Colleagues Think Of Litigation Finance
- Law Firm Doesn't Owe For GSK Contempt Order, 3rd Circ. Told
- Ex-Katten Atty's Expert Defends No-Work Consulting Deals
- Fed. Circ. Upholds Ruling Axing Forest's Namenda Patents
- Retailers Defend Solodyn MDL Claims Against Medicis
- Convicted Pharmacist's Wife Wants To Keep Money, House
- Endo Escapes Faulty Pelvic Mesh Suit On Appeal
- Supreme Court Won't Review Lawyer's Stock Fraud Conviction
- 1st Circ. Won't Revive $28M Monsanto PCB Liability Suit
- FDA Issues Final Guidance On Drug Names In Ads
- Puma Biotech Investor Class Certified In Stock Drop Case
- 40 Years Of FCPA: A View From The Monitorship Trenches
- The Law Firms Of The 2017 MVPs
- Law360 MVP Awards Go To Top Attorneys From 78 Firms
- Investor Hit With $38M Judgment For 'Smear' Campaign
- Pharma Group Sues Calif. Over Drug Pricing Law
- NJ High Court OKs Roche's Bids To Review Accutane Rulings
- Innoviva Investor Wins Board Seats In Chancery Proxy Suit
- Katten Atty Says He Never Saw Greebel Break The Law
- Patheon Says Rival Can't Recover $135M Over Softgel Pact
- Biotech Denali Therapeutics Tops 3 IPOs Totaling $506M
- Gilead Snaps Up PE-Backed Biotech In $567M Deal
- 40 Years Of FCPA: The Untold Story Of The Resource Guide
- Real Estate Brokerage Leads 3 IPOs Set To Raise $762M
- Deals Rumor Mill: Bayer, Toshiba, Alexion Pharmaceuticals
- Contractor Sues For $21M Over Bio Warfare Facility Work
- FDA Unveils New Policies On Digital Health Oversight
- Amgen Urges Full Fed. Circ. Hearing On Repatha Patents
- Feds Blast Ex-Pharmacist's Acquittal Bid In Meningitis Row
- Ex-Katten Atty Was Corporate Ace At Firm, Jury Hears
- Puma Exec's Brother Traded On Cancer Drug Info, SEC Says
- Covington Lures Back FDA Drug Quality Leader
- 40 Years Of FCPA: A Journey From Conviction To Dismissal
- 4th Circ. Frees Pfizer From Antitrust Suit Over Celebrex Patent
- 9th Circ. Vacates Drug Liability MDL Ruling Favoring Merck
- 2 Biotech Cos., Payday Lender Tap IPO Market For $307M
- Lab CEO Can't Be Named In FCA Retaliation Suit, Court Says
- Israel Chemicals Snags Roughly $1B In Sale To PE Firm
- Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement
- The Biggest Patent Cases Of 2017
- My Strangest Day In Court: The Shkreli Trial
- Prosecution In Greebel Case Rests After Hearing Last Witness
- 9th Circ. Affirms Doc's Rx Conviction But Nixes Sentence
- JPML Sends Opioid MDL To Northern Ohio
- Allergan Says Shire Suit Upends 'Very Fabric' Of Antitrust Law
- Tribe Hits Pharma Cos. Over Opioid Crisis
- Insurer Can't Recoup $9M Payout For Drug Theft: 3rd Circ.
- Opioid Suits Are The New Tobacco Litigation, Atty Says
- $28M Philly Xarelto Verdict Ripe For Reversal, Attys Say
- Gilstrap Can't Erase Jury's Patent Verdict, Fed. Circ. Hears
- 40 Years Of FCPA: The Siemens Lesson — Tillerson Is Right
- GAO Urges VA To Improve Medical Supply Purchase Program
- Celltrion Wants Janssen To Give Up Docs From Samsung Suit
- Roxane Fights Vanda Antipsychotic Dose Patent In Fed. Circ.
- Pharma Co. Slams Patent Challenge Standing In Fed. Circ.
- $110M Talc Verdict's Survival Eases Way For Out-Of-Staters
- Bovine Breeding Tech Co. Seeks To Revive Patent Claims
- Ex-Shire Employees Seek To Duck Trade Secrets Complaint
- Pa. Judge Affirms Jurisdiction On Out-Of-State Mesh Cases
- 9th Circ. Refuses To Rethink Ex-InterMune CEO's Conviction
- Mayer Brown Advises Nestle's $2.3B Deal For Nutrition Co.
- Merck Aims To Sink Cert In $250M Sex Bias Class Action
- 40 Years Of FCPA: The Rise In International Enforcement
- Beware Marketing Cannabidiol Products: FDA Is Watching
- Buyer Class Fights Allergan Over Causation In Antitrust Row
- J&J, Bayer Hit With $28M Verdict In 1st Xarelto Loss
- Montana AG Hits Purdue With Opioid Suit
- Tech, Generics Cos. Spar With Tribes Over Allergan At PTAB
- Patent Args Should've Gone To Jury, Fed Circ. Told
- Investors Tell 1st Circ. Sarepta Hid FDA Testing Issues
- Fla. Compounding Pharmacy Can't Escape Tricare FCA Suit
- FBI Pressured Witness With Surprise Visit, Greebel Atty Says
- Janssen Rips Patent Owner's Bid To Appeal Mid-Case
- Proactive Brand Protection Strategies For Pharma Innovators
- TPG Sweetens Deal For Medical Device Co. Exactech To $737M
- High Court Won't Hear Dow's Appeal Of $455M Bayer Award
- Justices Ask SG To Weigh In On Merck's Fosamax MDL
- 40 Years Of FCPA: Highlights From The 1st Corporate Trial
- Ex-Pharma Staffing Exec Wants Out Of Noncompete Suit
- Plavix Ruling Raises Learned Intermediary Questions
- Biotech Cos. Among 5 IPOs That Could Surpass $580M
- Pfizer, Dana-Farber Win Bid For Bristol-Myers Docs In IP Suit
- Philly Jury Set To Deliberate In Xarelto Injury Case
- 9th Circ. Says Gov't Still Party To Closed Lawsuit In FCA Row
- Pfizer Tells 2nd Circ. Feds Lack Immunity In $8.3M Tax Row
- FDA's Focus On Competition May Boost FTC Enforcement
- Deals Rumor Mill: Merck, Mednax, Volkswagen
- 40 Years Of FCPA: The Strange Case That Started It All
- Drug Co. Wants FOIA Answers From NIH Over Biotech Ties
- InSys Investor Suit Put On Hold As Criminal Action Plays Out
- Texas Justices Won't Hear Suit Over Newborn's Genetic Test
- Vitamin Cos. Want New Trial After $6.8M IP Verdict
- Feds Want Shkreli To Forfeit $7.3M, Wu-Tang Clan Album
- Pa. Judge Says No Preemption In Auxilium Testosterone Case
- MDL Hearing Signals A New Phase For Opioid Suits